Home
Valneva

Valneva Market Share Analysis for May 2026

Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.

Health > Biotechnology and Pharmaceuticals

Domainvalneva.com

Year Founded2013

Employees501 - 1000

Annual Revenue$100M - $200M

Valneva

Valneva (including company regionals)

valneva.com

See more website traffic and engagement information

Valneva Revenue up to May 2026 is 100M - 200M

revenue generated by Valneva top domains

Valneva top domains revenue over 3 years

Revenue for Valneva top domains

valneva.com100M - 200M

See more with Sales Intelligence

Total visits to Valneva's top domains

Understand Valneva market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

valneva.com32.4K

See more with Sales Intelligence

Avg. visit duration in Valneva's top domains

Analyze Valneva engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

valneva.com00:00:29

See more with Sales Intelligence

Avg. pageviews on Valneva's top domains

See how Valneva keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

valneva.com1.93

See more with Sales Intelligence

Valneva top competitors by domain

Top similar sites in May 2026, ranked by their affinity

dynavax.comCompany NameDynavax TechnologiesEmployees201 - 500HQUnited States, California, EmeryvilleAnnual revenue$200M - $500MTotal visits5.4KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Valneva

These are the website technologies, by industry, used by Valneva top domains

Payment & Currencies (12)

Cart Functionality

eCommerce (6)

Swap

Email Services (5)

Sendgrid

Widget (5)

Twemoji

More Technologies

10

See all

News & Signals from Valneva

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsValneva SE is developing vaccine to protect against Lyme disease on May 1st '26.Pharmaceutical companies Pfizer and Valneva announced this spring that they plan to seek regulatory approval for a vaccine to protect against Lyme disease.

NewsValneva SE had revenue of $36M on Jan 1st '26.Valneva reported first-quarter 2026 revenue of €30.9 million, nearly 40% below a year earlier, as its travel vaccine business shrank and the company prepared regulatory submissions for its Lyme disease vaccine LB6V.

NewsValneva SE is developing Lyme disease vaccine candidate.Topline results were announced from a phase 3 trial evaluating an investigational Lyme disease vaccine candidate (PF-07307405) being developed by Pfizer and Valneva.